Silo Pharma (SILO): Price to Sales

Corporate company logo of Silo Pharma, Inc. (SILO)

The price-to-sales trend on GURU.Markets reflects market expectations, where 58.90 indicates the level of this metric. Silo Pharma, Inc. (SILO) is implementing environmental standards in the creation of psychotropic agents to minimize ecological impact. The business operates as a virtual structure, outsourcing development to contractors. The absence of current sales makes pricing dependent on future regulatory decisions regarding drug approvals.

Silo Pharma, Inc. (SILO): P/S Multiple from 04/28/2023 to 11/14/2026

Metric breakdowns and analytics for Silo Pharma, Inc. (SILO)

- share price and consensus valuation forecast:
Price Performance Chart Silo Pharma Inc.|SILO - Price Target Chart
- stock exchange capitalization data:
Market Value Silo Pharma|SILO - Total Company Value
- shareholders' equity book value data:
Net Assets per Share Silo Pharma|SILO - Book Capitalization|Market Capitalization to Book Value silopharma.com|SILO - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Silo Pharma, Inc.|SILO - Long-Term Debt to Equity|Current Liabilities to Capital silopharma.com|SILO - Company Total Debt|Debt to Net Assets Ratio Silo Pharma|SILO - Company Long-Term Debt|Current Liabilities Silo Pharma|Intermediate Coverage Ratio silopharma.com
- net income and valuation ratios data:
SILO - Net Profit|Projected Future Earnings Silo Pharma, Inc.|SILO - Price to Earnings Ratio|Future Price to Earnings Multiple Silo Pharma Inc.|SILO - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Silo Pharma|SILO - Operating profit EBITDA|Net earnings per share (EPS TTM) Silo Pharma|SILO - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months silopharma.com|SILO - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Silo Pharma, Inc.
- issuer revenue and sales details:
SILO - Company Revenue|Company Revenue Forecast silopharma.com|SILO - P/S Multiple|Forward Price-to-Revenue Multiple Silo Pharma
Summary company analytics:Silo Pharma Inc., SILO
Product sample of Silo Pharma, Inc.

For an investor in the research business of Silo Pharma, Inc. (SILO), this metric serves as a tool for assessing the company's market value relative to its current sales. The ratio of market capitalization to annual revenue, visualized through the divergence of the P/S ratio from its historical average, allows for a comparison of asset value against operational efficiency under standard laboratory environmental costs, determining whether the business is overbought or undervalued.

Competitors of Silo Pharma, Inc.

ALKS (alkermes.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Avadel Pharmaceuticals plc AVDL|atai Life Sciences NV (ATAI) - Price to Sales|GHRS - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Mind Medicine Corp MNMD|CMPS: P/S Multiple|LBRX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Bright Minds Biosciences Inc.|Price-to-Revenue Ratio VNDA|Price-to-Revenue Ratio Cybin Inc. (CYBN)|ANRO - Price to Sales|NRx Pharmaceuticals - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CING|CPHI - Price-to-Revenue Ratio|Price-to-Sales Ratio CMND|PBM: P/S Multiple|SciSparc Corp - Market Capitalization-to-Revenue Ratio|SEEL (Seelos Therapeutics) - P/S Multiple|P/S Multiple Virpax|Price-to-Revenue Ratio Karuna Therapeutics, Inc. (KRTX)